Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Phase II Dose-Finding Study in Japanese AF Patients
NCT00973245Phase 2Completed
- Sponsor
- Bayer
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (4 arms), sponsored by Bayer. Primary endpoints: Incidence of bleeding and BAY 59-7939 concentrations / Factor Xa activity, PT, PT-INR, PTT and HEPTEST at Day 28. Started Jul 2006; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00973245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00973245.